Literature DB >> 35855097

Favorable outcome of repeat mechanical thrombectomy in a geriatric patient: illustrative case.

Ali A Alsarah1, Omar M Hussein1, Andrew P Carlson2.   

Abstract

BACKGROUND: The authors presented their experience with a case of repeat thrombectomy in a 93-year-old patient who showed a favorable outcome after recurrent large vessel occlusion treated with emergency mechanical thrombectomy. OBSERVATIONS: Mechanical thrombectomy has been proven to be effective in treating large vessel occlusion types of ischemic stroke. Most of the patient populations involved in the thrombectomy-related studies were younger than 80 years. In addition, recurrent mechanical thrombectomy is not a common procedure in clinical practice. This unusual case demonstrated the potential to achieve a favorable outcome with thrombectomy even in a patient older than 85 years with recurrent large vessel occlusion. LESSONS: There can be a favorable neurological outcome after one or repeat thrombectomies for geriatric patients older than 90 years, and age should not be a deterrent to treatment.
© 2021 The authors.

Entities:  

Keywords:  CT = computed tomography; CTA = CT angiography; DCA = diagnostic cerebral angiography; MCA = middle cerebral artery; MRI = magnetic resonance imaging; NIHSS = National Institutes of Health Stroke Scale; TICI = Thrombolysis in Cerebral Infarction; geriatric patients; ischemic stroke; large vessel occlusion; mRS = modified Rankin Scale; mechanical thrombectomy

Year:  2021        PMID: 35855097      PMCID: PMC9245837          DOI: 10.3171/CASE2140

Source DB:  PubMed          Journal:  J Neurosurg Case Lessons        ISSN: 2694-1902


From 2015 to 2018, seven trials (MR CLEAN,[1] REVA SCAT,[2] ESCAPE,[3] SWIFT PRIME,[4] EXTEND-1A,[5] DIFFUSE 3,[6] and DAWN[7]) provided evidence of increased functional independence without increasing the risk of death after the early performance of mechanical thrombectomy. Intravenous chemical thrombolysis and mechanical thrombectomy have become the gold standards for treating patients who experience acute ischemic stroke.[8] Despite its rarity, recurrent mechanical thrombectomy has been considered a relatively safe procedure. Bouslama et al.[9] found no statistically significant differences in demographics, stroke severity, time from last known normal to puncture, reperfusion rates, hemorrhagic complications, good clinical outcomes, and mortality between patients who underwent repeat thrombectomy and patients who had a single thrombectomy. That finding reflected a favorable neurological outcome.[9] The role of mechanical thrombectomy in patients older than 85 years has also been debated, given the overall risk of a worse outcome in this population. Recent studies, however, have shown that a patient population older than 85 years may still benefit from thrombectomy, especially with complete recanalization, despite the risk.[10] We present a case study of a 93-year-old woman who showed significant improvement in functional outcome after each of the two thrombectomies she underwent.

Illustrative Case

A 93-year-old woman with a past medical history of hypertension, hyperlipidemia, and gout presented with the acute onset of left-sided weakness and left-sided facial droop. She was last seen well at 1:00 pm, and her National Institutes of Health Stroke Scale (NIHSS) score upon arrival was 22. The patient received alteplase at 2:21 pm. A right middle cerebral artery (MCA) M1 occlusion was revealed on computed tomography angiography (CTA) and diagnostic cerebral angiography (DCA) (Fig. 1A). CTA showed mild calcified atherosclerotic plaques at the carotid bifurcation bilaterally but no significant intracranial atherosclerosis.
FIG. 1.

DCA. A: Acute right MCA M1 occlusion. B: After mechanical thrombectomy revascularization of the entire MCA territory with no evidence of distal thromboembolic complication or persistent occlusion.

DCA. A: Acute right MCA M1 occlusion. B: After mechanical thrombectomy revascularization of the entire MCA territory with no evidence of distal thromboembolic complication or persistent occlusion. The patient underwent successful right M1 mechanical thrombectomy and had a Thrombolysis in Cerebral Infarction (TICI) score of 3 at 4:15 pm (Fig. 1B). Her premorbid modified Rankin Scale (mRS) score was 0. Magnetic resonance imaging (MRI) of the brain showed restriction diffusion of the right basal ganglia without evidence of hemorrhage. Her discharge NIHSS score was 0. The etiology of the stroke was concluded to be cryptogenic after thorough stroke workup, including transthoracic echocardiography with bubble study, thyroid function test, and lipid profile, which did not reveal significant abnormality. She was discharged with instructions to take aspirin 81 mg and atorvastatin 80 mg daily. Fifty-two days later, at 10:27 am, the patient presented with the acute onset of left-sided weakness and slurred speech. Her NIHSS score upon arrival was 8. The patient was last seen well at 3:00 am and thus was not a candidate for chemical thrombolysis. Head computed tomography (CT) showed no acute infarct. CTA showed occlusion of the right proximal M2 superior division of the MCA. CT perfusion of the brain showed ischemic penumbra of 55 mL without an ischemic core in the respective vascular territory (Fig. 2A). She underwent mechanical thrombectomy at 12:10 pm with TICI 3 revascularization (Fig. 3). MRI showed small-to-moderate volume, right MCA territorial ischemic infarct with minimal petechial hemorrhage (Fig. 2B). Her NIHSS score at discharge was 0. Her collateral circulation assessment based on the CTA was overall good and was considered to have the following scores according to single-phase CTA collateral scores in acute stroke: Tan et al. = 2; Maas et al. = 2/3; Souza et al. = 2/3; Cristoforidis = 2; Miteff = 2; and ASPECTS = approximately 3.[11-18]
FIG. 2.

A: CT perfusion scans of head with contrast showing increase in time to maximum contrast intensity on the ct perfusion (Tmax) > 6 seconds in the right superior MCA territory. There is no decreased cerebral blood flow < 30%. B: Diffusion-weighted MRI, axial section, showing restricted diffusion in the right MCA territory notably involving right anterolateral frontal lobe, insula, and basal ganglia.

FIG. 3.

Second DCA showing (A) acute right MCA M2 occlusion and (B) post–mechanical thrombectomy revascularization of the entire MCA territory with no evidence of distal thromboembolic complication or persistent occlusion.

A: CT perfusion scans of head with contrast showing increase in time to maximum contrast intensity on the ct perfusion (Tmax) > 6 seconds in the right superior MCA territory. There is no decreased cerebral blood flow < 30%. B: Diffusion-weighted MRI, axial section, showing restricted diffusion in the right MCA territory notably involving right anterolateral frontal lobe, insula, and basal ganglia. Second DCA showing (A) acute right MCA M2 occlusion and (B) post–mechanical thrombectomy revascularization of the entire MCA territory with no evidence of distal thromboembolic complication or persistent occlusion. After her second stroke, a cardiac loop recorder was implanted. It did not reveal any evidence of dysrhythmia, which confirmed the diagnosis of cryptogenic stroke. The patient was started on apixaban 2.5 mg.

Discussion

Observations

The HERMES meta-analysis favored endovascular thrombectomy even in patient populations older than 80 years, noting that it significantly reduced disability at 90 days as compared to that in the standard medical treatment arm of the study.[19] This meta-analysis included 198 patients with an age ≥ 80 years, and the rate of an mRS score of 0 to 2 at 90 days was 29.8% in the endovascular group and 13.9% in the control group (OR 3.68, 95% CI 1.95–6.92). However, the rate of an mRS score of 0 to 2 at 90 days in the endovascular group decreased with advancing age: 50 to 59 years, 50.0%; 60 to 69 years, 51.9%; 70 to 79 years, 43.1%; and ≥ 80 years, 29.8%. Therefore, this meta-analysis suggested that age remained a strong independent negative predictor of outcome despite the treatment effect of mechanical thrombectomy. Imahori et al. demonstrated significant differences in procedure times for endovascular treatment between patients whose age was ≥ 80 years and those whose age was < 80.[18] They found that being 80 years or older was not a significant predictor for outcomes after mechanical thrombectomy (42% vs 57%, respectively; p = 0.261) or death (8% vs 5%, respectively; p = 0.653), whereas complete recanalization was an influential predictor with a positive outcome, particularly in those 80 years or older with complete recanalization (mTICI 3).[18] Recurrent mechanical thrombectomy is generally not contraindicated; in fact, it appears safe in properly selected patients with recurrent large vessel occlusion strokes. Bouslama et al.[9] studied a group of patients who underwent repeat thrombectomy. Although none of the selected patients was more than 90 years old, they showed favorable outcomes without a significant increased risk of intracranial hemorrhage or significant increase in the risk of death.[9] Six of the 15 patients involved in the study had ipsilateral (same stream) repeat thrombectomies. At 90 days, the mRS score for 4 of the 6 did not show worsening, 1 showed improvement, and 1 had a worse mRS score after a third stroke. A recent study by Lee et al. also concluded that ipsilateral repeat thrombectomies produced a significantly better clinical outcome when compared to that with contralateral repeat thrombectomies (83.3% vs 16.7, p = 0.027),[19] but none of the patients was older than 90 years.

Lessons

Repeat mechanical thrombectomy is an uncommon procedure in clinical practice, and to our knowledge, this is the first reported patient older than 90 years with a good functional outcome after both interventions. Although the overall outcomes in such patient populations may be worse than in younger populations and first-time thrombectomy patients, the current literature supports an aggressive approach even in these groups. The limitations of this approach for geriatric patients are multifactorial, including stroke size, medical comorbidities, operative and postoperative complications, and adverse effects of the secondary stroke prevention measures, which can further challenge the outcome. Further retrospective studies are necessary to analyze the benefits and challenges of performing thrombectomies in patients older than 90 years to build on the literature and find potential positive outcomes. Moreover, it is necessary to consider that as the aging population increases, more dynamic studies will be necessary to tend to these individuals.

Disclosures

Dr. Carlson reported other support from Cerebroscope outside the submitted work.

Author Contributions

Conception and design: all authors. Acquisition of data: Alsarah, Hussein. Analysis and interpretation of data: Alsarah, Hussein. Drafting the article: Carlson, Alsarah. Critically revising the article: Carlson, Hussein. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Carlson. Study supervision: Hussein.
  18 in total

1.  Comparison of four different collateral scores in acute ischemic stroke by CT angiography.

Authors:  Fatih Seker; Arne Potreck; Markus Möhlenbruch; Martin Bendszus; Mirko Pham
Journal:  J Neurointerv Surg       Date:  2015-12-09       Impact factor: 5.836

2.  Repeated Mechanical Thrombectomy in Recurrent Large Vessel Occlusion Acute Ischemic Stroke.

Authors:  Mehdi Bouslama; Diogo C Haussen; Leticia C Rebello; Jonathan A Grossberg; Michael R Frankel; Raul G Nogueira
Journal:  Interv Neurol       Date:  2016-09-09

3.  Malignant CTA collateral profile is highly specific for large admission DWI infarct core and poor outcome in acute stroke.

Authors:  L C S Souza; A J Yoo; Z A Chaudhry; S Payabvash; A Kemmling; P W Schaefer; J A Hirsch; K L Furie; R G González; R G Nogueira; M H Lev
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-01       Impact factor: 3.825

4.  A multicenter randomized controlled trial of endovascular therapy following imaging evaluation for ischemic stroke (DEFUSE 3).

Authors:  Gregory W Albers; Maarten G Lansberg; Stephanie Kemp; Jenny P Tsai; Phil Lavori; Soren Christensen; Michael Mlynash; Sun Kim; Scott Hamilton; Sharon D Yeatts; Yuko Palesch; Roland Bammer; Joe Broderick; Michael P Marks
Journal:  Int J Stroke       Date:  2017-03-24       Impact factor: 5.266

5.  Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct.

Authors:  Raul G Nogueira; Ashutosh P Jadhav; Diogo C Haussen; Alain Bonafe; Ronald F Budzik; Parita Bhuva; Dileep R Yavagal; Marc Ribo; Christophe Cognard; Ricardo A Hanel; Cathy A Sila; Ameer E Hassan; Monica Millan; Elad I Levy; Peter Mitchell; Michael Chen; Joey D English; Qaisar A Shah; Frank L Silver; Vitor M Pereira; Brijesh P Mehta; Blaise W Baxter; Michael G Abraham; Pedro Cardona; Erol Veznedaroglu; Frank R Hellinger; Lei Feng; Jawad F Kirmani; Demetrius K Lopes; Brian T Jankowitz; Michael R Frankel; Vincent Costalat; Nirav A Vora; Albert J Yoo; Amer M Malik; Anthony J Furlan; Marta Rubiera; Amin Aghaebrahim; Jean-Marc Olivot; Wondwossen G Tekle; Ryan Shields; Todd Graves; Roger J Lewis; Wade S Smith; David S Liebeskind; Jeffrey L Saver; Tudor G Jovin
Journal:  N Engl J Med       Date:  2017-11-11       Impact factor: 91.245

6.  Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score.

Authors:  P A Barber; A M Demchuk; J Zhang; A M Buchan
Journal:  Lancet       Date:  2000-05-13       Impact factor: 79.321

7.  Angiographic assessment of pial collaterals as a prognostic indicator following intra-arterial thrombolysis for acute ischemic stroke.

Authors:  Gregory A Christoforidis; Yousef Mohammad; Dimitris Kehagias; Bindu Avutu; Andrew P Slivka
Journal:  AJNR Am J Neuroradiol       Date:  2005-08       Impact factor: 3.825

8.  Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke.

Authors:  Jeffrey L Saver; Mayank Goyal; Alain Bonafe; Hans-Christoph Diener; Elad I Levy; Vitor M Pereira; Gregory W Albers; Christophe Cognard; David J Cohen; Werner Hacke; Olav Jansen; Tudor G Jovin; Heinrich P Mattle; Raul G Nogueira; Adnan H Siddiqui; Dileep R Yavagal; Blaise W Baxter; Thomas G Devlin; Demetrius K Lopes; Vivek K Reddy; Richard du Mesnil de Rochemont; Oliver C Singer; Reza Jahan
Journal:  N Engl J Med       Date:  2015-04-17       Impact factor: 91.245

9.  A randomized trial of intraarterial treatment for acute ischemic stroke.

Authors:  Olvert A Berkhemer; Puck S S Fransen; Debbie Beumer; Lucie A van den Berg; Hester F Lingsma; Albert J Yoo; Wouter J Schonewille; Jan Albert Vos; Paul J Nederkoorn; Marieke J H Wermer; Marianne A A van Walderveen; Julie Staals; Jeannette Hofmeijer; Jacques A van Oostayen; Geert J Lycklama à Nijeholt; Jelis Boiten; Patrick A Brouwer; Bart J Emmer; Sebastiaan F de Bruijn; Lukas C van Dijk; L Jaap Kappelle; Rob H Lo; Ewoud J van Dijk; Joost de Vries; Paul L M de Kort; Willem Jan J van Rooij; Jan S P van den Berg; Boudewijn A A M van Hasselt; Leo A M Aerden; René J Dallinga; Marieke C Visser; Joseph C J Bot; Patrick C Vroomen; Omid Eshghi; Tobien H C M L Schreuder; Roel J J Heijboer; Koos Keizer; Alexander V Tielbeek; Heleen M den Hertog; Dick G Gerrits; Renske M van den Berg-Vos; Giorgos B Karas; Ewout W Steyerberg; H Zwenneke Flach; Henk A Marquering; Marieke E S Sprengers; Sjoerd F M Jenniskens; Ludo F M Beenen; René van den Berg; Peter J Koudstaal; Wim H van Zwam; Yvo B W E M Roos; Aad van der Lugt; Robert J van Oostenbrugge; Charles B L M Majoie; Diederik W J Dippel
Journal:  N Engl J Med       Date:  2014-12-17       Impact factor: 91.245

10.  CT angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct.

Authors:  I Y L Tan; A M Demchuk; J Hopyan; L Zhang; D Gladstone; K Wong; M Martin; S P Symons; A J Fox; R I Aviv
Journal:  AJNR Am J Neuroradiol       Date:  2009-01-15       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.